Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal down2.340 -0.090 (-3.704%)
Others

22/01/2021 17:48

Sino Biopharm (01177) medicine passes consistency evaluation

[ET Net News Agency, 22 January 2021] Sino Biopharmaceutical Limited (01177) said the
oncology medicine "Bortezomib for Injection" (product name: Qianping) (specifications:
1.0mg and 3.5mg) of the group has obtained the notice of approval of supplemental
applications issued by the National Medical Products Administration of the People's
Republic of China, and has passed the Consistency of Quality and Efficacy Evaluation for
Generic Drugs.
Bortezomib is a proteasome inhibitor with anti-tumour effects in targeted therapy, which
is applicable to the treatment of Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL).
Bortezomib is a fundamental drug for the treatment of myeloma. (RC)

Back to Others

Remark: Real time quote last updated: 19/04/2024 15:58
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.